Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RO6958688 |
| Trade Name | |
| Synonyms | RG7802|Cibisatamab|CEA-TCB|RO-6958688 |
| Drug Descriptions |
RO6958688 (cibisatamab) is a bispecific antibody that binds to CD3 and human anti-carcinoembryonic antigen (CEA) simultaneously, which may lead to cytotoxic immune response against CEA-positive tumor cells (PMID: 30982469). |
| DrugClasses | CD3 Antibody 119 |
| CAS Registry Number | 1855925-27-7 |
| NCIT ID | C120097 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Obinutuzumab + RO6958688 | Atezolizumab Obinutuzumab RO6958688 | 0 | 1 |
| Atezolizumab + RO6958688 | Atezolizumab RO6958688 | 0 | 2 |
| Obinutuzumab + RO6958688 + RO7122290 | Obinutuzumab RO6958688 RO7122290 | 0 | 1 |
| RO6958688 | RO6958688 | 0 | 0 |